Memorial Sloan Kettering

Site:	Memorial Sloan Kettering	Go to their website
Address:	1275 York Ave
City:	New York
State:	NY
Zip:	10065
Country:	USA

44 trials at this site

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
1b/2	MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	Imatinib + MEK162	NCT01991379
1/2	A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Active, not recruiting	Closed	THE-630	NCT05160168
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
2	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	Active, not recruiting	Active, not recruiting	LOXO-101	NCT02576431
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Active	Rogaratinib	NCT04595747
1	Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Active, not recruiting	Closed	Nivolumab + BMS-986016	NCT01968109
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862
1	A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	Binimetinib + Pexidartinib	NCT03158103
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT02571036
1	Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody	Active, not recruiting	Closed	HuF9-G4	NCT02216409
1	A Study of XmAb®18087 in Subjects With NET and GIST	Active, not recruiting	Closed	XmAb18087	NCT03411915
1/2	BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Completed	Closed	Imatinib + BGJ398	NCT02257541
3	SU011248 in Treating Patients With Malignant Gastrointestinal Stromal Tumor	Completed	Closed	Sunitinib	NCT00085618
2	An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment	Completed	Closed	BIIB021 (CNF2024)	NCT00618319
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
2	Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma	Completed	Closed	Nivolumab + Ipilimumab	NCT02500797

Memorial Sloan Kettering

44 trials at this site

Page 1 of 3 | Next | Last